Capsule Commentaries: Selected Oral Antifungal Drug-Drug Interactions with Itraconazole and Terbinafine
Main Article Content
Keywords
antifungal, drug-drug interaction, itraconazole, terbinafine, therapy
Abstract
This article provides a review of selected drug-drug interactions with itraconazole and terbinafine that are clinically relevant with potential for toxicity. These include itraconazole and certain statin agents, itraconazole and digoxin, and terbinafine and some antidepressants, with commentary suggestions on management.
References
Shear N, Drake L, Gupta AK, et al. The implications and management of drug interactions with itraconazole, fluconazole and terbinafine. Dermatology. 2000;201(3):196-203.
Dybro AM, Damkier P, Rasmussen TB, et al. Statin-associated rhabdomyolysis triggered by drug-drug interaction with itraconazole. BMJ Case Rep. 2016 Sep 7;2016. pii: bcr2016216457.
Tatro DS. Drug Interactions Facts, Wolters Kluwer Health Inc, St. Louis, Missouri, USA, 2005, p 718.
Alderman CP, Allcroft PD. Digoxin-itraconazole interaction: possible mechanisms.
Ann Pharmacother. 1997;31(4):438-440.
Angirasa AK, Koch AZ. P-glycoprotein as the mediator of itraconazole-digoxin interaction. J Am Podiatr Med Assoc. 2002;92(8):471-472.
Jalava KM, Partanen J, Neuvonen PJ. Itraconazole decreases renal clearance of digoxin. Ther Drug Monit. 1997 Dec;19(6):609-13.
Van Der Kuy PH, Van Den Heuvel HA, Kempen RW, et al. Pharmacokinetic interaction between nortriptyline and terbinafine. Ann Pharmacother. 2002;36(11):1712-1714.
Castberg I, Helle J, Aamo TO. Prolonged pharmacokinetic drug interaction between terbinafine and amitriptyline. Ther Drug Monit. 2005 Oct;27(5):680-2.
Tatro DS. Drug Interactions Facts, Wolters Kluwer Health Inc, St. Louis, Missouri, USA, 2005, p 1507.
Yasui-Furukori N, Saito M, Inoue Y, et al. Terbinafine increases the plasma concentration of paroxetine after a single oral administration of paroxetine in healthy subjects. Eur J Clin Pharmacol. 2007;63(1):51-56.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.